Perspective Therapeutics, Inc. (NYSE:CATX) CFO Acquires $49,006.78 in Stock

Perspective Therapeutics, Inc. (NYSE:CATX) CFO Jonathan Robert Hunt bought 12,829 shares of the company’s stock in a transaction dated Monday, November 25th. The stock was acquired at an average price of $3.82 per share, for a total transaction of $49,006.78. Following the acquisition, the chief financial officer now directly owns 48,800 shares in the company, valued at $186,416. This trade represents a 35.66 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Perspective Therapeutics Stock Down 6.4 %

Shares of Perspective Therapeutics stock opened at $4.12 on Friday. The stock has a 50 day moving average price of $10.78 and a two-hundred day moving average price of $12.32. Perspective Therapeutics, Inc. has a 12-month low of $2.28 and a 12-month high of $19.05.

Perspective Therapeutics (NYSE:CATX) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.21) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.21). The business had revenue of $0.37 million for the quarter. Perspective Therapeutics had a negative net margin of 4,096.66% and a negative return on equity of 27.40%. On average, analysts predict that Perspective Therapeutics, Inc. will post -0.87 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of brokerages have recently weighed in on CATX. Cantor Fitzgerald reiterated an “overweight” rating on shares of Perspective Therapeutics in a report on Monday, September 9th. Truist Financial began coverage on Perspective Therapeutics in a report on Wednesday, September 25th. They issued a “buy” rating and a $21.00 price objective on the stock. Royal Bank of Canada dropped their price objective on Perspective Therapeutics from $25.00 to $16.00 and set an “outperform” rating on the stock in a report on Monday. Wedbush restated an “outperform” rating and issued a $11.00 price objective (down previously from $20.00) on shares of Perspective Therapeutics in a report on Thursday, November 21st. Finally, UBS Group began coverage on Perspective Therapeutics in a report on Thursday, October 24th. They issued a “buy” rating and a $20.00 price objective on the stock. One investment analyst has rated the stock with a hold rating and eight have given a buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $15.14.

Institutional Investors Weigh In On Perspective Therapeutics

Institutional investors have recently bought and sold shares of the business. nVerses Capital LLC bought a new position in shares of Perspective Therapeutics during the third quarter valued at $57,000. US Bancorp DE raised its holdings in shares of Perspective Therapeutics by 142.7% in the third quarter. US Bancorp DE now owns 6,576 shares of the company’s stock valued at $88,000 after buying an additional 3,866 shares during the last quarter. Victory Capital Management Inc. bought a new stake in Perspective Therapeutics during the 2nd quarter worth about $117,000. Point72 DIFC Ltd bought a new stake in Perspective Therapeutics during the 2nd quarter worth about $118,000. Finally, Intech Investment Management LLC bought a new stake in Perspective Therapeutics during the 3rd quarter worth about $137,000. Institutional investors and hedge funds own 54.66% of the company’s stock.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.